Literature DB >> 12626445

Simple method to distinguish between primary and secondary C3 deficiencies.

Marlene Pereira de Carvalho Florido1, Patrícia Ferreira de Paula, Lourdes Isaac.   

Abstract

Due to the increasing numbers of reported clinical cases of complement deficiency in medical centers, clinicians are now more aware of the role of the complement system in the protection against infections caused by microorganisms. Therefore, clinical laboratories are now prepared to perform a number of diagnostic tests of the complement system other than the standard 50% hemolytic component assay. Deficiencies of alternative complement pathway proteins are related to severe and recurrent infections; and the application of easy, reliable, and low-cost methods for their detection and distinction are always welcome, notably in developing countries. When activation of the alternative complement pathway is evaluated in hemolytic agarose plates, some but not all human sera cross-react to form a late linear lysis. Since the formation of this linear lysis is dependent on C3 and factor B, it is possible to use late linear lysis to routinely screen for the presence of deficiencies of alternative human complement pathway proteins such as factor B. Furthermore, since linear lysis is observed between normal human serum and primary C3-deficient serum but not between normal human serum and secondary C3-deficient serum caused by the lack of factor H or factor I, this assay may also be used to discriminate between primary and secondary C3 deficiencies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626445      PMCID: PMC150543          DOI: 10.1128/cdli.10.2.216-220.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  15 in total

Review 1.  Systemic lupus erythematosus, complement deficiency, and apoptosis.

Authors:  M C Pickering; M Botto; P R Taylor; P J Lachmann; M J Walport
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Reactive haemolysis--a distinctive form of red cell lysis.

Authors:  R A Thompson; D S Rowe
Journal:  Immunology       Date:  1968-05       Impact factor: 7.397

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Deficiency of C3 inactivator in man.

Authors:  N Abramson; C A Alper; P J Lachmann; F S Rosen; J H Jandl
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

5.  Complement factor I deficiency in a family with recurrent infections.

Authors:  M F Leitão; M M Vilela; R Rutz; A S Grumach; A Condino-Neto; M Kirschfink
Journal:  Immunopharmacology       Date:  1997-12

6.  Complement haemolytic activity (classical and alternative pathways), C3, C4 and factor B titres in healthy children.

Authors:  V P Ferriani; J E Barbosa; I F de Carvalho
Journal:  Acta Paediatr       Date:  1999-10       Impact factor: 2.299

7.  Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H.

Authors:  N Amadei; G V Baracho; V Nudelman; W Bastos; M P Florido; L Isaac
Journal:  Scand J Immunol       Date:  2001-06       Impact factor: 3.487

8.  Hereditary human complement C3 deficiency owing to reduced levels of C3 mRNA.

Authors:  A G Ulbrich; M P Florido; V Nudelman; E S Reis; G V Baracho; L Isaac
Journal:  Scand J Immunol       Date:  2001-06       Impact factor: 3.487

9.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

10.  Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7.

Authors:  R A Thompson; P J Lachmann
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.